dolutegravir/lamivudine/tenofovir disoproxil fumarate / Cipla, Laurus Labs, Aurobindo, Viatris, Hetero, Macleods - LARVOL DELTA

Pharmacokinetics of Dolutegravir, nucleoside analogues, and intracellular metabolites using plasma separation cards: A comparative analysis with traditional sampling methods in healthy volunteers. (PubMed, PLoS One) - P1 | "This study provides important insights into the elimination kinetics of NRTI, their intracellular metabolites and DTG. Plasma separation cards are a promising alternative for adherence monitoring, enabling simultaneous quantification of parent and intracellular moieties from a single sample. Differences in TFV-DP levels between TDF and TAF regimens, and DBS sampling method, underscore the need for matrix and regimen-specific interpretation to validate adherence benchmarks."

Clinical • Journal • PK/PD data

Longitudinal analysis of metabolic changes in people with HIV on integrase inhibitor-based versus efavirenz-based therapy: a prospective real-world cohort study in China. (PubMed, BMC Infect Dis) - "INSTI-based ART was associated with sustained weight gain but did not worsen long-term dyslipidemia compared to an EFV-based regimen in a real-world setting. Hepatic steatosis correlated with metabolic parameters rather than INSTI exposure."

Journal • Real-world evidence • Dyslipidemia • Human Immunodeficiency Virus • Infectious Disease • Metabolic Disorders

Low burden of clinically relevant anaemia and thrombocytopenia among adolescents living with HIV receiving tenofovir/lamivudine plus dolutegravir: the CIPHER-ADOLA study in Cameroon. (PubMed, AIDS Res Ther) - "In the TLD era, anaemia remains common but generally mild, and thrombocytopenia is uncommon. Cytopenias were associated with unsuppressed viral load, with a stronger association for anaemia in females. These findings support programmatic targeted haemovigilance prioritising adolescents with unsuppressed viral load, particularly females, in settings where access to FBC testing is limited."

Journal • Anemia • Hematological Disorders • Human Immunodeficiency Virus • Infectious Disease • Thrombocytopenia • CD4

Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis (clinicaltrials.gov) - P2 | N=30 | Completed | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting ➔ Completed

Trial completion • Human Immunodeficiency Virus • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis • CD4

Long-Acting Antiretroviral Therapy for Breastfeeding Women With HIV Experiencing Barriers to Adherence in Zimbabwe: Modeling Clinical Impact and Cost-effectiveness. (PubMed, J Infect Dis) - "LA-ART for breastfeeding women experiencing adherence challenges could reduce infant infections. If efficacies and costs are confirmed, LA-ART for NVS women would improve outcomes and be minimally cost-saving; for VS women, LA-ART would be cost-effective in Zimbabwe at costs ≤$84/year."

HEOR • Journal • Human Immunodeficiency Virus • Infectious Disease • Pediatrics

Virological and drug-resistance outcomes for people living with HIV initiating or switching to tenofovir, lamivudine, and dolutegravir in six PEPFAR-supported countries: a prospective cohort study. (PubMed, Lancet HIV) - "High rates of viral suppression in response to tenofovir-lamivudine-dolutegravir therapy in individuals who had suppression before switching support international treatment guidelines for this population. Findings on resistance mutations and tenofovir diphosphate concentrations suggest that incomplete adherence was a key factor in the suboptimal outcomes of people with virological failure at the time of switching treatment."

Journal • Human Immunodeficiency Virus • Infectious Disease

Prevalence and risk factors of adverse drug events with dolutegravir-based regimens among Thai people living with HIV: a retrospective cohort study. (PubMed, AIDS Res Ther) - "Over half (53.86%) of patients on long-term DTG-based therapy experienced at least one ADE. Risk was significantly elevated in older adults, those with psychiatric illness, previous cryptococcosis, underweight status, or lower baseline eGFR. Healthcare providers should implement proactive monitoring and tailored management strategies for these high-risk patients to optimize ART safety and efficacy outcomes."

Adverse events • Journal • Retrospective data • Hematological Disorders • Human Immunodeficiency Virus • Infectious Disease • Mental Retardation • Psychiatry

Viral suppression and associated factors after enhanced adherence counseling among people living with HIV with unsuppressed viral loads at tertiary and first-level health facilities in Zambia: A retrospective cohort study. (PubMed, PLOS Glob Public Health) - "Participants on tenofovir/lamivudine/dolutegravir were 29% more likely to suppress compared to those on zidovudine/lamivudine/dolutegravir. Other key factors influencing suppression were community-based delivery and prior six-month MMD. Findings highlight opportunities to integrate technology-enhanced adherence support and differentiated service delivery models to optimize HIV care outcomes."

Journal • Retrospective data • Human Immunodeficiency Virus • Infectious Disease

Sustained HIV Suppression With Co-formulated Tenofovir Disoproxil Fumarate/Lamivudine/Dolutegravir in a Person With Transmitted Dolutegravir Resistance and Pretreatment Resistance to Lamivudine: a Case Report From HPTN 083. (PubMed, Open Forum Infect Dis) - "HIV phenotyping confirmed that the transmitted virus had DTG and 3TC resistance but retained susceptibility to DTG at higher drug concentrations. Pharmacologic testing indicated that the DTG concentrations observed in this case were sufficient to overcome the effects of 2 major baseline INSTI resistance mutations (G140S and Q148H)."

Journal • Human Immunodeficiency Virus • Infectious Disease

Differences in growth trajectories in breastfed HIV-exposed uninfected and HIV-unexposed infants in Kenya: An observational cohort study. (PubMed, PLoS Med) - "Despite breastfeeding and optimal maternal dolutegravir-based ART, CHEU experienced growth deficits compared to CHU in the first two years of life. Continued monitoring of the expanding CHEU population is essential in the context of rapidly evolving guidelines and policies to optimize their health and to identify and prevent future health disparities and disease risks."

Journal • Observational data • CNS Disorders • Depression • Hematological Disorders • Human Immunodeficiency Virus • Infectious Disease • Psychiatry

A Multi-center Randomized Clinical Trial on BIC/FTC/TAF vs DTG+3TC+TDF in People with HIV Who Experience Virologic Failure in China (ChiCTR) - P=N/A | N=374 | Recruiting | Sponsor: Beijing Youan Hospital, Capital Medical University; Beijing Youan Hospital, Capital Medical University

New trial • Human Immunodeficiency Virus • Infectious Disease

Viral hepatitis B co-infection among people living with HIV: a National cross-sectional survey in Togo in 2023. (PubMed, BMC Infect Dis) - "HBV prevalence is high among PLWH, especially in northern Togo, and the HBV viral load is suppressed in almost all patients on ART treatment. One third of our study population was susceptible to HBV infection, and in urgent need of HBV vaccination."

Journal • Hepatitis B • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation

Distribution and efficacy of dolutegravir-based regimens in the main HIV outpatient care in Caracas, Venezuela. (PubMed, AIDS Res Ther) - "A high viral suppression rate of over 90% was documented for all DTG-based regimens, with no significant difference found between the main regimen (DTG/3TC/TDF) and its alternatives: DTG/emtricitabine/tenofovir alafenamide (TAF), abacavir/3TC + DTG and, DTG/3TC. Overall, almost all switches (97.1%) were made toward DTG/FTC/TAF. Osteoporosis was the main reason for switching treatments (80.1%)."

Journal • Human Immunodeficiency Virus • Infectious Disease • Osteoporosis • Rheumatology

Applying Hickam's Dictum in an Immunosuppressed Patient: A Case Report of Strongyloidiasis, Giardiasis, in a Newly Diagnosed Patient with HIV/AIDS in Rural Kenya (ASTMH 2025) - "In this newly diagnosed patient with HIV/AIDS, she was started on antiretroviral treatment of tenofovir disoproxil fumarate/lamivudine/dolutegravir 1 tablet orally daily. This case highlights the importance of applying Hickam's Dictum diagnostically in an immunosuppressed host—and, how concluding with one diagnosis to explain the clinical syndrome would be insufficient."

Case report • Clinical • Cardiovascular • Cough • Gastrointestinal Disorder • Human Immunodeficiency Virus • Infectious Disease • Malaria • Respiratory Diseases • Tuberculosis

High rates of viral suppression in pregnancy drop postpartum in South African women on tenofovir-lamivudine-dolutegravir: a prospective cohort study. (PubMed, J Int AIDS Soc) - "High rates of VS were maintained during pregnancy and early postpartum, but substantial viraemia emerged by 24 weeks postpartum, jeopardizing maternal and child health outcomes. These unique data provide further impetus to explore innovative approaches to supporting adherence among WHIV during the postpartum period."

Journal • Human Immunodeficiency Virus • Infectious Disease • Pediatrics • CD4

Clinical case of advanced HIV with multiple opportunistic diseases: pneumocystis pneumonia, CMV chorioretinitis, and Kaposi’s sarcoma (EACS 2025) - "Therapy was initiated with oxygen, ganciclovir, trimethoprim-sulfamethoxazole (TMP-SMX), supportive care, and ART (DTG/3TC/TDF). This case highlights that, even in advanced stages of HIV with profound immune compromise and delayed treatment, comprehensive and timely intervention can lead to significant clinical improvement and virologic suppression and may be life-saving"

Clinical • Metastases • Cytomegalovirus Infection • Human Immunodeficiency Virus • Infectious Disease • CD4

Mpox as a chronic active infection in a patient living with HIV/AIDS: clinical and virological implications in a year of evolution (EACS 2025) - "Tecovirimat was initiated (14-day course) alongside ART (TDF/3TC/DTG once daily). The final PCR-positive lesion was documented 14 months after symptom onset. Four samples collected during this period were sequenced, all belonging to clade IIb, lineage B.1.1 (Figure 2), indicating persistent infection rather than reinfection."

Clinical • Human Immunodeficiency Virus • Infectious Disease • CD4

Case report: late diagnosis of HIV at clinical stage 4 with pulmonary and CNS tuberculosis (EACS 2025) - "GeneXpert testing of CSF and sputum was positive for M. tuberculosis, with no rifampicin resistance...The healthcare client was started on anti-tuberculosis therapy (HRZE regimen), ART (DTG/3TC/TDF), and prophylactic TMP-SMX... While mass brain lesions in advanced HIV are often attributed to toxoplasmosis, lymphoma, or PML, CNS tuberculosis should be considered. Despite a late HIV diagnosis, comprehensive treatment and ART adherence can lead to favorable outcomes."

Case report • Clinical • Metastases • Hepatitis B • Human Immunodeficiency Virus • Infectious Disease • Tuberculosis • CD4

Durability of viral suppression following antiretroviral therapy optimization to TLD among treatment-experienced adults living with HIV in Tajikistan (EACS 2025) - "Purpose : Tajikistan started antiretroviral therapy (ART) optimization with tenofovir/lamivudine/dolutegravir (TLD) in 2019...Conclusions : Transitioning to TLD resulted in high rates of DVS among all PLHIV in Tajikistan. Prioritizing TLD scale up and DVS monitoring are important activities to support positive client-level outcomes."

Clinical • Human Immunodeficiency Virus • Infectious Disease

A Randomized Controlled Trial Evaluating Virologic and Renal Outcomes After Switching from TDF+FTC or 3TC+EFV to TDF/3TC/DTG (TLD) Versus DTG+3TC in Virologically Suppressed Thai PWH - A Pilot Study. (PubMed, Curr HIV Res) - "Dual therapy with DTG + 3TC may be a preferable switch option over TLD for virologically suppressed PWH with renal safety concerns."

Journal • Human Immunodeficiency Virus • Infectious Disease • Nephrology • Renal Disease • CD4 • CST3

Three-Year Outcomes After Programmatic Transitioning to Dolutegravir in the Context of Severe Civil Unrest in Haiti. (PubMed, Open Forum Infect Dis) - "Tenofovir disoproxil fumarate/lamivudine/dolutegravir (TLD) is widely prescribed in low and middle-income countries. Virologic outcomes on TLD are outstanding for PWH with pre-switch suppression. However, rates of virologic suppression are suboptimal among PWH who were ART-naïve at TLD initiation, and among those with a history of pre-switch failure, additional interventions are necessary, including access to long-acting treatment regimens."

Journal • Human Immunodeficiency Virus • Infectious Disease

Viral suppression in adults on efavirenz- or dolutegravir-based antiretroviral therapy in Mopani District, South Africa. (PubMed, South Afr J HIV Med) - "Clients aged ≥ 15 years initiated on tenofovir-lamivudine-dolutegravir (TLD) or tenofovir-emtricitabine-efavirenz (TEE) between 01 October 2021 and 31 March 2023, with ≥ 150 days in care, were included. The high proportion of clients with low-level viraemia is concerning. All clients, regardless of regimen, need evaluation for adherence support."

Journal • Human Immunodeficiency Virus • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

HIV resistance to dolutegravir varies with co-administered agents. (PubMed, Clin Infect Dis) - "Multivariable analysis of 183 viremic (≥200c/mL) participants from four cohorts (N=660 participants) found dolutegravir-resistance in 21 (11.5%). Dolutegravir-resistance was greater with dolutegravir+lamivudine+zidovudine/(one on stavudine) (OR=19.4, 95%CI 5.1-74.3) or dolutegravir+lamivudine+abacavir (OR=5.4, 95%CI 1.1-25.8), compared to dolutegravir+lamivudine+tenofovir."

Journal • Human Immunodeficiency Virus • Infectious Disease

Effect of Weight Gain on Blood Pressure in Ugandan Persons with HIV on Dolutegravir/Lamivudine/ Tenofovir Disoproxil Fumarate over 48 weeks. (IDWeek 2025) - No abstract available

Human Immunodeficiency Virus • Infectious Disease

The experience of poor sleep of living with HIV in Indonesia: Toward an Intervention Development (WSS 2025) - "Further data analysis was based on a hermeneutic form of PLHIV narratives three themes were developed: 1) I have a lot of things in my mind that prevent me from sleeping; 2) I would rather switch to TLD (Tenofovir Lamivudine Dolutegravir) so that I can have my sleep back; 3) When I can't sleep, I end up scrolling through my phone. HIV-positive status and any HIV medication taken may affect PLHIV's sleeping pattern. However, there are many potentials to improve the sleep health of Indonesian PLHIV."

CNS Disorders • Human Immunodeficiency Virus • Infectious Disease • Insomnia • Sleep Disorder